HIV activists have appealed to pharmaceutical companies to ensure that all countries across the world can access lenacapavir.
Lenacapavir is a Prep drug that is to be administered twice a year was proven to be successful in preventing Hiv infections.
The appeal follows a recent decision by “HIV infection” the company behind the recent successful studies on drugs, to grant royalty free licenses to 6 generic drug manufacturers in a move to make it affordable in low and lower middle income countries.
Addressing health journalists during a media engagement from east and South Africa Mitchell Warren the Executive Director AVAC a non government organisation working on HIV prevention and equity said although the granting of licences to generic manufacturers is good, it is not good enough is some countries are left out
Warren said that although a few companies are granted licences, Gilead pharmaceuticals is moving fast to ensure that lenacapavir is accessible to people who need it.
Now Nelly Mungo Rwamba a senior gynecologists and scientist involved in HIV and cervical cancer prevention research said despite having affordability issues, people should be out at the centre of all HIv treatment and prevention product development
